CA2407083A1 - Derive de peptides apo-ai/aii - Google Patents

Derive de peptides apo-ai/aii Download PDF

Info

Publication number
CA2407083A1
CA2407083A1 CA002407083A CA2407083A CA2407083A1 CA 2407083 A1 CA2407083 A1 CA 2407083A1 CA 002407083 A CA002407083 A CA 002407083A CA 2407083 A CA2407083 A CA 2407083A CA 2407083 A1 CA2407083 A1 CA 2407083A1
Authority
CA
Canada
Prior art keywords
peptide
apo
domain
matter
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002407083A
Other languages
English (en)
Inventor
Tadahiko Kohno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2407083A1 publication Critical patent/CA2407083A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

L'invention concerne des agents thérapeutiques imitant l'activité du peptide hélice amphipathique Apo-AI. Ces composés comprennent: (a) un peptide hélice amphipatique Apo-AI ou un domaine mimétique du peptide hélice amphipatique Apo-AI, de préférence, la séquence aminoacide SEQ ID NO:7, ou des séquences dérivées de cette dernière par déploiement de phages, criblage de peptides d'ARN ou les autres techniques mentionnées ci-dessus; (b) un véhicule, tel qu'un polymère (par exemple PEG ou dextrane) ou un domaine Fc, qui est préféré. Ce véhicule, de préférence un domaine Fc, est lié de façon covalente au peptide hélice amphipathique Apo-AI ou au domaine mimétique de ce peptide. Le véhicule et le peptide hélice amphipathique Apo-AI ou le domaine mimétique de ce peptide peuvent être reliés par la terminaison N ou C du peptide hélice amphipathique Apo-AI ou de son domaine mimétique, comme décrit ci-dessous. Le véhicule préféré consiste en un domaine Fc et le domaine Fc préféré consiste en un domaine IgGFc. Le peptide hélice amphipathique Apo-AI ou les domaines mimétiques du peptide hélice amphipathique Apo-AI comprennent les séquences aminoacides décrites dans la table 1. On peut générer d'autres peptides hélices amphipathiques Apo-AI ou des domaines mimétiques du peptide hélice amphipathique Apo-AI par déploiement de phages, criblage de peptides d'ARN et autres techniques décrites.
CA002407083A 2000-04-21 2001-04-23 Derive de peptides apo-ai/aii Abandoned CA2407083A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19892000P 2000-04-21 2000-04-21
US60/198,920 2000-04-21
PCT/US2001/013068 WO2001081376A2 (fr) 2000-04-21 2001-04-23 Derive de peptides apo-ai/aii

Publications (1)

Publication Number Publication Date
CA2407083A1 true CA2407083A1 (fr) 2001-11-01

Family

ID=22735445

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002407083A Abandoned CA2407083A1 (fr) 2000-04-21 2001-04-23 Derive de peptides apo-ai/aii

Country Status (12)

Country Link
US (1) US6743778B2 (fr)
EP (1) EP1290013B1 (fr)
JP (1) JP2003530870A (fr)
AT (1) ATE319737T1 (fr)
AU (2) AU2001257173B2 (fr)
CA (1) CA2407083A1 (fr)
DE (1) DE60117781T2 (fr)
DK (1) DK1290013T3 (fr)
ES (1) ES2260219T3 (fr)
MX (1) MXPA02010324A (fr)
PT (1) PT1290013E (fr)
WO (1) WO2001081376A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2407086A1 (fr) * 2000-04-21 2001-11-01 Amgen, Inc. Antagonistes d'integrine/d'adhesion
US8116889B2 (en) * 2002-06-27 2012-02-14 Openpeak Inc. Method, system, and computer program product for managing controlled residential or non-residential environments
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7329725B1 (en) 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
BRPI0406605B8 (pt) * 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
EP1827472A4 (fr) * 2004-12-06 2012-09-05 Univ California Procedes pour l'amelioration de la structure et de la fonction d'arterioles
US7704953B2 (en) * 2006-02-17 2010-04-27 Mdrna, Inc. Phage displayed cell binding peptides
US8790678B2 (en) * 2006-03-03 2014-07-29 Washington University Biomaterials having nanoscale layers and coatings
CA2653840A1 (fr) * 2006-06-01 2007-12-06 Institut De Cardiologie De Montreal Utilisation d'un complexe de peptides/phospholipides agissant comme un agoniste inverse de transport de lipide pour le traitement de la stenose valvulaire
AU2014268255B2 (en) * 2009-02-16 2016-04-21 Cerenis Therapeutics Holding Sa Apolipoprotein a-i mimics
SI2396017T1 (sl) 2009-02-16 2015-12-31 Cerenis Therapeutics Holding Sa Mimika apolipoproteina A-1
WO2015173633A2 (fr) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Marqueurs de thérapie hdl
BR112017020491A2 (pt) 2015-03-25 2018-07-17 The Regents Of The University Of Michigan composições e métodos para distribuição de agentes de biomacromolécula.
CA3032229A1 (fr) 2016-07-27 2018-02-01 Hartis-Pharma Sa Combinaisons therapeutiques pour traiter les troubles des globules rouges
IL297336A (en) 2020-04-16 2022-12-01 Abionyx Pharma Sa Methods for the treatment of serious conditions by lipid binding complexes of basic proteins
AU2021354095A1 (en) 2020-10-01 2023-06-08 Abionyx Pharma Sa Compositions comprising lipid binding protein-based complexes for use for treating eye diseases
JP2024514154A (ja) 2021-04-15 2024-03-28 アビオニクス ファーマ エスエー 臓器保存溶液における脂質結合タンパク質ベースの複合体の使用
WO2023194797A1 (fr) 2022-04-06 2023-10-12 Abionyx Pharma Sa Méthodes de traitement de maladies oculaires faisant appel à des complexes à base de protéines de liaison aux lipides
WO2023194798A1 (fr) 2022-04-06 2023-10-12 Abionyx Pharma Sa Procédés de traitement de la leucocytose, la dysfonction endothéliale et de la cardite à l'aide de complexes à base de protéines de liaison aux lipides
WO2023237935A2 (fr) 2022-06-10 2023-12-14 Abionyx Pharma Sa Méthodes de traitement d'affections aiguës à l'aide de complexes à base de protéines se liant à des lipides
WO2023237927A2 (fr) 2022-06-10 2023-12-14 Abionyx Pharma Sa Méthodes de traitement de pathologies hyperinflammatoires à l'aide de complexes à base de protéines liant les lipides

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1023287A (fr) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Procede de fixation d'une proteine sur un substrat
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (fr) 1977-02-17 1981-01-20 Hideo Hirohara Traduction non-disponible
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
NL8720442A (nl) 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
CA2118130A1 (fr) 1992-04-14 1993-10-28 Jean M. J. Frechet Macromolecules composees de polymeres dendritiques et methode de production
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
WO1997034631A1 (fr) * 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Domaines analogues a l'immunoglobuline a demi-vies prolongees
WO1998009602A2 (fr) * 1996-09-05 1998-03-12 The Uab Research Foundation Peptides anti-atherosclereux et modele murin transgenique d'atherosclerose
AU4474497A (en) 1996-10-08 1998-05-05 U-Bisys B.V. Methods and means for selecting peptides and proteins having specific affinity for a target
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
GB9815505D0 (en) * 1998-07-16 1998-09-16 Adprotech Plc Polypeptide derivatives
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents

Also Published As

Publication number Publication date
EP1290013A2 (fr) 2003-03-12
EP1290013B1 (fr) 2006-03-08
US6743778B2 (en) 2004-06-01
WO2001081376A2 (fr) 2001-11-01
ATE319737T1 (de) 2006-03-15
DE60117781T2 (de) 2006-11-23
AU5717301A (en) 2001-11-07
JP2003530870A (ja) 2003-10-21
AU2001257173B2 (en) 2005-09-22
MXPA02010324A (es) 2003-04-25
ES2260219T3 (es) 2006-11-01
DE60117781D1 (de) 2006-05-04
US20030040470A1 (en) 2003-02-27
DK1290013T3 (da) 2006-06-26
WO2001081376A3 (fr) 2003-01-09
PT1290013E (pt) 2006-06-30

Similar Documents

Publication Publication Date Title
US6677136B2 (en) Glucagon antagonists
AU2001257173B2 (en) Apo-ai/aii peptide derivatives
AU2001257321B2 (en) Parathyroid hormone and parathyroid hormone-related protein antagonists
EP1921088B1 (fr) Peptides et molécules associées qui sont liées à tall-1
EP1439852B1 (fr) Peptides et composes apparentes ayant une activite thrombopoietique
AU2001257173A1 (en) Apo-AI/AII peptide derivatives
AU2001257321A1 (en) Parathyroid hormone and parathyroid hormone-related protein antagonists
JP2007084558A (ja) 治療薬としての修飾ペプチド
CA2407086A1 (fr) Antagonistes d'integrine/d'adhesion
US20020090646A1 (en) Calcitonin-related molecules
AU2002359391A1 (en) Modulators of receptors for parathyrois hormone and parathyroid hormone-related protein
AU2005211578A1 (en) Integrin/adhesion antagonists
AU2007201923A1 (en) Peptides and related compounds having thrombopoietic activity
AU2002340176A1 (en) Peptides and related compounds having thrombopoietic activity

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued